Optimization of 1,3-disubstituted urea-based inhibitors of Zika virus infection
2019
Abstract Zika virus (ZIKV) has become a public health concern worldwide due to its association with congenital abnormalities and neurological diseases. To date, no effective vaccines or antiviral drugs have been approved for the treatment of ZIKV infection, and new inexpensive therapeutic options are urgently needed. In this study, we have used an in vitro plaque assay to assess an antiviral activity of the second generation of anti-ZIKV compounds, based on 1,3-disubstituted (thio)urea scaffold. Several compounds in the library were found to possess excellent activity against Zika virus with IC50 values
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
45
References
3
Citations
NaN
KQI